We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Nanoparticle-Based Laboratory Immunoassay Determines 5-FU Plasma Levels

By LabMedica International staff writers
Posted on 13 Aug 2008
A nanoparticle-based laboratory immunoassay provides oncologists with a new tool for monitoring blood levels of 5-fluorouracil (5-FU) in cancer patients undergoing chemotherapy. The test is faster than currently available methods, enabling personalized dose management with the goal of minimizing toxicity and maximizing the therapeutic benefit of 5-FU treatment.

5-FU alone, or in combination with other drugs, is an important chemotherapeutic agent for treatment of colorectal cancer, the third most diagnosed cancer worldwide. The therapeutic window between toxicity and efficacy of 5-FU is very narrow and very difficult to maintain through clinical examination alone. Current dosing is based on body surface area (BSA), which can result in up to 50-fold variability in patient blood levels. While BSA is the standard, studies report that there is no correlation between plasma clearance of the drug, exposure to the drug, and BSA.

Saladax Biomedical (Bethlehem, PA, USA) has signed an agreement with Karolinska University Hospital (Stockholm, Sweden to supply the novel 5-FU personalized chemotherapy management (PCM) reagent kits. Karolinska is the first European institution to offer the novel, nanoparticle-based laboratory immunoassay for determining 5-FU plasma levels (for continuous infusion regimens) with advantages of speed and small sample size. Automation and rapid turnaround time will enable efficient routine monitoring of 5-FU concentrations in clinical practice for therapeutic drug monitoring.

Dr. Hakan Gadler, chief medical officer at Saladax, commented, "The ability to personalize chemotherapy is a significant advance in the treatment of cancer and one that will lead to improved efficacy and fewer side effects for patients. Individually adjusted chemotherapy dosing provides great benefits to patients, a meaningful new tool for oncologists, and cost savings to the healthcare system."

Related Links:
Saladax Biomedical
Karolinska University Hospital



New
Gold Member
Collection and Transport System
PurSafe Plus®
Portable Electronic Pipette
Mini 96
New
HBV DNA Test
GENERIC HBV VIRAL LOAD VER 2.0
New
Capillary Blood Collection Tube
IMPROMINI M3

Latest Molecular Diagnostics News

New DNA Methylation-Based Method Predicts Cancer Progression
13 Aug 2008  |   Molecular Diagnostics

Urine Test Could Predict Outcome of Cartilage Transplant Surgery
13 Aug 2008  |   Molecular Diagnostics

2-Hour Cancer Blood Test to Transform Tumor Detection
13 Aug 2008  |   Molecular Diagnostics